This clinical trial is focused on studying a disease called unresectable pleural mesothelioma, which is a type of cancer that affects the lining of the lungs and cannot be removed through surgery. The study is testing a new treatment option that combines a medication called volrustomig (also known by its code name MEDI5752) with two other drugs, carboplatin and pemetrexed. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The trial will compare this new combination treatment to other standard treatments, which include either a combination of nivolumab and ipilimumab or a combination of platinum-based drugs with pemetrexed.
The purpose of the study is to determine if the new treatment combination is more effective in improving the overall survival of patients with pleural mesothelioma compared to the standard treatments. Participants in the study will receive one of the treatment options and will be monitored over time to assess their response to the treatment and any side effects they may experience. The study will also look at other factors such as how long the treatment works, the time it takes for the disease to progress, and the overall response rate to the treatment.
Throughout the study, participants will undergo regular check-ups, which may include physical exams, blood tests, and other assessments to monitor their health and the effects of the treatment. The trial aims to provide valuable information that could lead to better treatment options for people with pleural mesothelioma in the future.
Belgium 
Denmark 
France 
Germany 
Italy 
Norway 
Poland 
Spain 
The Netherlands